在PD-L1高表达和/或ER低表达的乳腺肿瘤中，新辅助治疗nivolumab的收益最高

{"title":"在PD-L1高表达和/或ER低表达的乳腺肿瘤中，新辅助治疗nivolumab的收益最高","authors":"Marten Dooper","doi":"10.55788/b2fd44f8","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":516760,"journal":{"name":"Medicom Conference Report SABCS 2023","volume":"51 3-4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Highest benefit of neoadjuvant nivolumab in breast tumours with high PD-L1 expression and/or low ER expression\",\"authors\":\"Marten Dooper\",\"doi\":\"10.55788/b2fd44f8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":516760,\"journal\":{\"name\":\"Medicom Conference Report SABCS 2023\",\"volume\":\"51 3-4\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medicom Conference Report SABCS 2023\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.55788/b2fd44f8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medicom Conference Report SABCS 2023","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55788/b2fd44f8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}